Abstract
AbstractAnkylosing spondylitis is a male-predominant disease and previous study revealed that estrogens have an anti-inflammatory effect on the spondyloarthritis (SpA) manifestations in zymosan-induced SKG mice. This study aimed to evaluate the effect of selective estrogen receptor modulator (SERM) lasofoxifene (Laso) on disease activity of SpA. Mice were randomized into zymosan-treated, zymosan + 17β-estradiol (E2)-treated, and zymosan + Laso-treated groups. Arthritis was assessed by 18F-fluorodeoxyglucose (18F-FDG) small-animal positron emission tomography/computed tomography and bone mineral density (BMD) was measured. Fecal samples were collected and 16S ribosomal RNA gene sequencing was used to determine gut microbiota differences. Both zymosan + E2-treated mice and zymosan + Laso-treated mice showed lower arthritis clinical scores and lower 18F-FDG uptake than zymosan-treated mice. BMD was significantly higher in zymosan + E2-treated mice and zymosan + Laso-treated mice than zymosan-treated mice, respectively. Fecal calprotectin levels were significantly elevated at 8 weeks after zymosan injection in zymosan-treated mice, but it was not significantly changed in zymosan + E2-treated mice and zymosan + Laso-treated mice. Gut microbiota diversity of zymosan-treated mice was significantly different from zymosan + E2-treated mice and zymosan + Laso-treated mice, respectively. There was no significant difference in gut microbiota diversity between zymosan + E2-treated mice and zymosan + Laso -treated mice. Laso inhibited joint inflammation and enhanced BMD in SKG mice, a model of SpA. Laso also affected the composition and biodiversity of gut microbiota. This study provides new knowledge regarding that selected SpA patients could benefit from SERM treatment.
Funder
Soonchunhyang University Research Fund
Ministry of Health & Welfare
Publisher
Springer Science and Business Media LLC
Reference48 articles.
1. Lee, W. et al. Are there gender differences in severity of ankylosing spondylitis? Results from the PSOAS cohort. Ann. Rheum. Dis. 66, 633–638. https://doi.org/10.1136/ard.2006.060293 (2007).
2. Ortega Castro, R. et al. Different clinical expression of patients with ankylosing spondylitis according to gender in relation to time since onset of disease. Data from REGISPONSER. Reumatol. Clin. 9, 221–225. https://doi.org/10.1016/j.reuma.2012.09.008 (2013).
3. Jeong, H. et al. Clinical characteristics of nonradiographic axial spondyloarthritis in Korea: A comparison with ankylosing spondylitis. Int. J. Rheum. Dis. 18, 661–668. https://doi.org/10.1111/1756-185x.12458 (2015).
4. Taneja, V. Sex Hormones Determine Immune Response. Front. Immunol. 9, 1931. https://doi.org/10.3389/fimmu.2018.01931 (2018).
5. Jimenez-Balderas, F. J., Tapia-Serrano, R., Madero-Cervera, J. I., Murrieta, S. & Mintz, G. Ovarian function studies in active ankylosing spondylitis in women. Clinical response to estrogen therapy. J. Rheumatol. 17, 497–502 (1990).
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献